Western blot analysis further showed that Nrf2 and HO-1 protein levels were significantly elevated in the NASH group compared to controls, and these were dose-dependently reduced by APE treatment (Figure 13e). Here, NFE2L2 is linked to metabolic dysfunction-associated steatohepatitis.